Patents Assigned to Biogen Idec
  • Patent number: 7456255
    Abstract: The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes peptides, proteins and antibodies that block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: November 25, 2008
    Assignees: Yale University, Biogen Idec MA Inc.
    Inventors: Stephen Strittmatter, Richard L. Cate, Dinah W. Y. Sah
  • Publication number: 20080286269
    Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.
    Type: Application
    Filed: July 10, 2006
    Publication date: November 20, 2008
    Applicant: Biogen Idec MA.
    Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W.T. van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
  • Patent number: 7452530
    Abstract: This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.
    Type: Grant
    Filed: April 21, 2004
    Date of Patent: November 18, 2008
    Assignees: Biogen Idec MA Inc., Emory University
    Inventors: Jeffrey L. Browning, Maryann Puglielli, Rafi Ahmed
  • Patent number: 7452534
    Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).
    Type: Grant
    Filed: July 10, 2000
    Date of Patent: November 18, 2008
    Assignee: Biogen Idec Inc.
    Inventors: Nabil Hanna, Roland Anthony Newman, Mitchell Elliot Reff
  • Publication number: 20080279853
    Abstract: Methods of treating cancer using an agent that blocks interaction between TWEAK and its receptor are described.
    Type: Application
    Filed: November 26, 2007
    Publication date: November 13, 2008
    Applicant: Biogen Idec MA Inc.
    Inventors: Linda C. Burkly, Jennifer Michaelson
  • Patent number: 7446173
    Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.
    Type: Grant
    Filed: March 16, 2004
    Date of Patent: November 4, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
  • Patent number: 7442370
    Abstract: A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: October 28, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Dinah Wen-Yee Sah, R. Blake Pepinsky, Paula Ann Boriack-Sjodin, Stephan S. Miller, Anthony Rossomando, Laura Silvian
  • Publication number: 20080262795
    Abstract: A system and method for monitoring process equipment includes collecting information from the process equipment. The collected information is statistically analyzed. One or more signatures indicating the overall status or health of one or more pieces of equipment can be developed.
    Type: Application
    Filed: February 23, 2006
    Publication date: October 23, 2008
    Applicant: Biogen Idec MA Inc
    Inventors: Marcus Webb, Soumitra Mishra
  • Publication number: 20080260728
    Abstract: Methods of treating multiple sclerosis are disclosed.
    Type: Application
    Filed: August 18, 2005
    Publication date: October 23, 2008
    Applicant: BIOGEN IDEC MA INC.
    Inventor: Michael Panzara
  • Patent number: 7438906
    Abstract: Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: October 21, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Publication number: 20080249287
    Abstract: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.
    Type: Application
    Filed: August 18, 2005
    Publication date: October 9, 2008
    Applicant: Biogen Idec MA Inc.
    Inventors: Anthony Rossomando, R. Blake Pepinsky, Bangjian Gong
  • Patent number: 7432240
    Abstract: Fumaric acid amides of the general formula (I) wherein R1 represents OR3 or a D- or L-amino acid radical —NH—CHR4—COOH bonded via an amide bond, wherein R3 is hydrogen, a straight-chained or branched, optionally substituted C1-24 alkyl radical, a phenyl radical or C6-10 aralkyl radical and R4 is a side chain of a natural or synthetic amino acid and R2 represents a D- or L-amino acid radical —NH—CHR5—COOH bonded via an amide bond or a peptide radical comprising 2 to 100 amino acids bonded via an amide bond, wherein R5 is a side chain of a natural or synthetic amino acid, are used for preparing a drug (1) for the therapy of an autoimmune disease; (2) for use in transplantation medicine; (3) for the therapy of mitochondrial diseases; or (4) for the therapy of NF-kappaB mediated diseases.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: October 7, 2008
    Assignee: Biogen Idec International GmbH
    Inventors: Rajendra Kumar Joshi, Hans-Peter Strebel
  • Publication number: 20080241163
    Abstract: Anti-Tweak antibodies are described.
    Type: Application
    Filed: November 26, 2007
    Publication date: October 2, 2008
    Applicant: Biogen Idec MA Inc.
    Inventors: Linda C. Burkly, Ellen Garber, Alexey Lugovskoy
  • Patent number: 7429644
    Abstract: Humanized antibodies to LT-?-R and methods of use thereof are provided.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: September 30, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Ellen Garber, Paul Lyne, Jose William Saldanha
  • Patent number: 7429645
    Abstract: This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-?-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the use of the antibodies alone or in combination with chemotherapeutic agent(s) in therapeutic methods.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: September 30, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Ellen Garber, Kenneth Simon, Jose William Saldanha
  • Publication number: 20080233647
    Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
    Type: Application
    Filed: February 12, 2008
    Publication date: September 25, 2008
    Applicants: BIOGEN IDEC MA INC., NSGENE A/S
    Inventors: Dinah W.Y. Sah, Teit E. Johansen, Anthony Rossomando
  • Publication number: 20080234271
    Abstract: The present invention relates in part to compounds of formulas (I) and (III): and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The present invention also relates to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a subject.
    Type: Application
    Filed: April 28, 2005
    Publication date: September 25, 2008
    Applicants: ICOS Corporation, Biogen Idec MA Inc.
    Inventors: Kevin Guckian, Daniel Scott, Irina Jacobson, C.Gregory Sowell
  • Patent number: 7427403
    Abstract: This invention relates to compositions and methods comprising “lymphotoxin-? receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-? receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-? receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: September 23, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman
  • Publication number: 20080226626
    Abstract: A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.
    Type: Application
    Filed: August 17, 2007
    Publication date: September 18, 2008
    Applicant: Biogen Idec Inc.
    Inventors: Kandasamy Hariharan, Nabil Hanna
  • Publication number: 20080227198
    Abstract: A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.
    Type: Application
    Filed: August 17, 2007
    Publication date: September 18, 2008
    Applicant: Biogen Idec Inc.
    Inventors: Kandasamy Hariharan, Nabil Hanna